ADMA BIOLOGICS, INC. (ADMA) research

ADMA BIOLOGICS, INC.
ShareXLinkedInReddit
Sector
Biotechnology
Last price
$9.81
As of

ADMA BIOLOGICS, INC. (ADMA): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.

As of . Source: SEC EDGAR filings for ADMA. Method and limitations.

SHARE THIS CARD

Share the ADMA intelligence card

A branded snapshot of ADMA: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion ADMA intelligence card preview
Post to X
LIVE TERMINAL

See ADMA live in the terminal

Track ADMA's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live ADMA terminal, free

Active signals for ADMA

FREE, NO ACCOUNT

Every signal on ADMA, as it fires

You are seeing 5 of 31 signals recorded on ADMA since 2026-07-24.

The five above landed across 2 days. The other 26 were recorded on 2 other days. 28 of the 31 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in ADMA (2026Q2)

Manager / securityMarket value% portfolioQoQ
D. E. Shaw & Co., Inc.CUSIP 000899104 · 2026Q2$44.1M0.02%,
TWO SIGMA INVESTMENTS, LPCUSIP 000899104 · 2026Q2$16.9M0.01%,
CITADEL ADVISORS LLCCUSIP 000899104 · 2026Q2$11.5M0.00%,
MILLENNIUM MANAGEMENT LLCCUSIP 000899104 · 2026Q2$9.7M0.00%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 000899104 · 2026Q2$5.5M0.01%,
Point72 Asset Management, L.P.CUSIP 000899104 · 2026Q2$3.5M0.00%,
Bridgewater Associates, LPCUSIP 000899104 · 2026Q2$3.4M0.01%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, ADMA

ADMA against its peers

ADMA's operating margin of 37.5% ranks in the 90th percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.

MetricADMAPeer medianPercentilen
Revenue FY510M USD108M USD8314
Gross margin57.4%n/an/a2
Operating margin37.5%-100.5%9014
Net margin28.8%-76.6%7815
Return on equity30.8%-26.6%9218
P / E16.4xn/an/a3

Peers (21): RAPP, AGIO, MESO, VIR, CMPS, KOD, VCEL, GHRS, URGN, ZYME, ZBIO, STOK, BHVN, PVLA, SEPN, XNCR, LKFT, SRPT, BCRX, AUPH, NTLA. Left out: COAG (no annual filing), GENB (no annual filing), BRVE (no annual filing), KARD (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ADMA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more ADMA signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ADMAand get the insider, 13F, options, and confluence read in one view.

Open the live ADMA terminal, free